Drug Type AAV based gene therapy |
Synonyms GT 005, PPY 988, PPY-988 + [1] |
Target |
Mechanism CFI stimulants(complement factor I stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Age Related Macular Degeneration | Phase 2 | US | 12 Jul 2022 | |
Age Related Macular Degeneration | Phase 2 | AU | 12 Jul 2022 | |
Age Related Macular Degeneration | Phase 2 | FR | 12 Jul 2022 | |
Age Related Macular Degeneration | Phase 2 | DE | 12 Jul 2022 | |
Age Related Macular Degeneration | Phase 2 | ES | 12 Jul 2022 | |
Age Related Macular Degeneration | Phase 2 | GB | 12 Jul 2022 | |
dry age-related macular degeneration | Phase 2 | US | 14 Jul 2020 | |
dry age-related macular degeneration | Phase 2 | AU | 14 Jul 2020 | |
dry age-related macular degeneration | Phase 2 | FR | 14 Jul 2020 | |
dry age-related macular degeneration | Phase 2 | DE | 14 Jul 2020 |
Phase 1/2 | 28 | sywqbfnetb(gznunotrip) = ffgoafppte bdzqahlnwb (gcvdvsjstn ) View more | Positive | 30 Sep 2021 |